Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “FIBROSARCOMA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,405 records · Page 78Linked to original sources
PubMed2003

Real-time GFP imaging of spontaneous HT-1080 fibrosarcoma lung metastases.

Metastasis to the lung is often a lethal event in sarcoma as well as other cancers. We report here a new animal model of sarcoma enabling the external real-time fluorescence imaging of spontaneous lung metastasis. The human fibrosarcoma cell line HT-1080 was transduced with the green fluorescent protein (GFP) gene. HT-1080-GFP cells were injected into the right hind footpad of severe combined immunodeficient (SCID) mice. The lung metastases were evaluated by whole-body fluorescence imaging as well as direct-view imaging in live animals through a skin-flap window over the chest wall. Spontaneous lung metastases were observed on the lungs of 11 of 12 mice. SCID mice well tolerated the skin-flap procedure enabling real-time imaging of spontaneous lung metastases with a resolution of approximately 50-100 microm. This procedure enabled external imaging at the micrometastasis level. Real-time evaluation of spontaneous lung metastasis in the same animals should allow drug evaluation and mechanistic studies not previously possible.

Animals↗
PubMed2001

Ameloblastic fibrosarcoma of the mandible: report of two cases and review of the literature.

Ameloblastic fibrosarcoma (AFS) is a rare malignant odontogenic tumour. To date, 60 well-documented cases have been published in the English-language literature. Two additional cases located in the posterior region of the mandible are reported. The relevant clinicopathological features of these cases, as well as those previously reported are discussed. Approximately two-thirds of AFS are malignant tumors de novo, with an average age of the affected patients being 22.9 years. This age is lower than the one observed in AFS developing from a pre-existent benign lesion (mean 33 years). Although regional and distant metastases are very infrequent, AFS is a locally aggressive lesion, with 23 (37%) of the reported cases having at least one recurrence; 12 patients (19.3%) died of the disease. Wide surgical excision with long-term follow-up remains the treatment of choice for this neoplasm.

Adult↗
PubMed1999

N-glycan structures of matrix metalloproteinase-1 derived from human fibroblasts and from HT-1080 fibrosarcoma cells.

Matrix metalloproteinase-1 (MMP-1) is a collagenolytic metalloproteinase capable of cleaving native triple-helical forms of several collagen subtypes, as well as a number of non-collagenous substrates. The role of MMP-1 in various diseases affecting the connective tissue is well characterized. MMP-1 is secreted as both glycosylated and unglycosylated species, and the two forms have been shown to be identical with respect to substrate specificity, specific activity and inhibitory profile. No function for the glycan moiety of the enzyme has been ascribed to date. In the present study, we report on the detailed characterization of MMP-1-derived oligosaccharides. Using strategies based on sequential exoglycosidase digestion combined with matrix-assisted laser desorption ionization-time of flight MS and electrospray tandem MS, we have characterized the N-glycan structures of MMP-1, derived from human dermal fibroblasts and from the HT-1080 fibrosarcoma cell line. MMP-1 derived from fibroblasts was found to carry mainly alpha 2,3-sialylated complex-type diantennary glycans. On the other hand, HT-1080 cells produce MMP-1 that has a heterogeneous glycosylation pattern, comprising diantennary glycans carrying Lewis X, LacdiNAc, sialylated LacdiNAc and GalNAc beta 1,4 (Fuc alpha 1,3)GlcNAc (LacdiNAc analogue of Lewis X) as terminal elements. We also show that, of the two potential glycosylation sites in the MMP-1 sequence, only Asn120 is used.

Carbohydrate Sequence↗
PubMed1996

The oxidative metabolism of glutamine. A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in L929 fibrosarcoma cells.

Treatment of the mouse fibrosarcoma cell line L929 with tumor necrosis factor (TNF) induces necrotic cell death. A crucial step in the cytotoxic action mechanism of TNF involves perturbation of mitochondrial functions leading to the formation of reactive oxygen intermediates (ROI). L929 cells have energy requirements adapted to a high proliferation rate. Glutamine (Gln) is utilized as a major energy source and drives mitochondrial ATP formation, while glucose is mainly converted to lactate through glycolysis. We investigated the role of the bioenergetic pathways involved in substrate utilization on the cytotoxic action of TNF and established a link between Gln oxidation and TNF-induced mitochondrial distress. Omission of Gln from the medium desensitizes the cells to TNF cytotoxicity, while the lack of glucose in the medium does not alter the TNF response. Sudden depletion of Gln from the culture medium results in a sharp decline in mitochondrial respiration in the cells, which might explain the decreased TNF responsiveness. However, when L929 cells are adapted to long term growth under conditions without Gln, these so-called L929/Gln- cells have restored respiration, but they still display a decreased sensitivity to TNF cytotoxicity. Thus the TNF responsiveness of L929 cells depends on bioenergetic reactions that are specifically involved in the oxidation of Gln. This is further confirmed by the desensitizing effect of specific inhibitors of these Gln-linked enzyme reactions on TNF cytotoxicity in the parental cells, but not in the L929/Gln- cells. Analysis of the induction of mitochondrial ROI formation by TNF in parental and L929/Gln- cells suggests that the effect of Gln on the sensitivity to TNF cytotoxicity involves a mechanism that renders the mitochondria more susceptible to TNF-induced mediators, resulting in enhanced ROI production and accelerated cytotoxicity.

Animals↗
PubMed2007

Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma.

The junctional adhesion molecule (JAM) family is a key molecule in a process called transendothelial migration or diapedesis. Here, we report implications of JAM-C in cancer metastasis. We first determined the mRNA expression of JAMs in 19 kinds of cancer cell lines. JAM-C was expressed in most of tumors having potent metastatic properties. Especially in murine K-1735 melanoma cell lines, the highly metastatic sublines (M2 and X21) strongly expressed JAM-C when compared with the poorly metastatic ones (C-10 and C23). Next, we investigated the role of JAM-C in cancer metastasis by using human JAM-C (hJAM-C) gene-transfected HT1080 fibrosarcoma cells. In comparison with mock-transfected HT1080 cells, these cells showed a significant increase in the adhesion to various extracellular substrates and the invasion across a Matrigel-coated membrane. The knockdown of hJAM-C using small interfering RNA resulted in the suppression of both the adhesion and the invasion of HT1080 cells, suggesting that endogenous hJAM-C might be involved in tumor metastasis. Finally, we studied the role of hJAM-C in an in vivo experimental metastatic model. The results showed that the overexpression of hJAM-C in HT1080 cells significantly decreased the life spans of the tumorbearing mice. In contrast, the knockdown of hJAM-C in HT1080 cells suppressed the weight gain of the lungs with metastatic colonies. We conclude that the expression of JAM-C promotes metastasis by enhancing both the adhesion of cancer cells to extracellular matrices and the subsequent invasion.

Animals↗
PubMed1978

Tissue enzyme changes in parabiotic rats with subcutaneous lymphoma or fibrosarcoma.

A solid lymphoma implanted into normal inbred Kx rats and one partner of parabiotic pairs caused appreciable decreases in hepatic ornithine aminotransferase and arginase about a week earlier (4-6 days after implantation) in single hosts than in parabiotic hosts. By 18-21 days significant decreases in both enzymes were apparent in the host partner also. The hepatic thymidine kinase showed a fivefold elevation in single hosts 4 days after implantation; by 14 days in its levels were about 200 times above normal and had also risen in the parabiotic hosts (20-fold) and host partners (fourfold). Implantation of fibrosarcoma caused qualititatively similar but generally less pronounced changes in these three enzymes in livers of single hosts, parabiotic hosts, and host partners. The splenic thymidine kinase 14 days after implantation was increased from control levels of about 3 U/g to 50.6, 44.8, and 13.5 U/g in single hosts, parabiotic hosts, and host partners, respectively. At later stages, 17-20 days after implantation of the lymphoma, appreciable amounts of thymidine kinase appeared in the plasma: The units of activity per milliliter were 6.2 in single hosts, 0.79 in parabiotic hosts, and 0.55 in host partners (control less than 0.05). Our observations on the changes in hepatic and splenic enzymes in parabiotic rats suggest that effects of neoplasms on distant host tissues are mediated by humoral factors. The less pronounced responses in parabiotic than in single hosts indicate that the tumor-free partner affords some "protection" against these systemic effects.

Animals↗
PubMed1979

Correlation between concanavalin A agglutinability and cytotoxic sensitivity to antiserum against tumor-associated antigen in rat fibrosarcoma cells.

An ip transplantation of 3-methylcholanthrene-induced, transplanted fibrosarcoma KMT-17 cells (1 X 10(8)) grew rapidly and killed syngeneic WKA rats in 3-4 days. Agglutinability induced by concanavalin A (Con A) and antigenic expression of KMT-17 cells were investigated in relation to days after ip transplantation. Agglutinability was highest in 1-day-old cells and lowest in 3-day-old cells. The agglutinability of 3-day-old cells increased again when these cells were transplanted into normal rats. The cytotoxic sensitivity of tumor cells to antiserum against tumor-associated surface antigen (TASA) changed simultaneously with the degree of Con A agglutinability. This phenomenon disappeared after artificial infection of tumor cells with Friend murine leukemia virus. The result of the quantitative absorption test at 4 degrees C overnight was that 1- and 3-day-old cells did not differ in their absorbing capacities to anti-TASA sera. However, when the absorption test was done at 37 degrees C for 60 minutes, 1-day-old cells had approximately 16 times more absorbing capacity than 3-day-old cells. However, the cytotoxic sensitivity to antiserum against histocompatibility antigen did not change, regardless of the number of days after ip transplantation. Analysis based on the quantitative absorption test revealed no difference in antibody-absorbing capacities between 1- and 3-day-old cells at both 4 degrees C and 37 degrees C. The relationship between Con A agglutinability and cytotoxic sensitivity to anti-TASA serum is discussed from the viewpoint of "lateral receptor mobility" on the cell surface.

Animals↗
PubMed1993

Simultaneous assessment of migration and proliferation of murine fibrosarcoma cells, as affected by hydroxyurea, vinblastine, cytochalasin B, Razoxane and interferon.

Using porous cell culture chambers, we have simultaneously assessed growth and locomotion of cancer cells to investigate whether certain agents affect cell motility in addition to cell division. First, cells from a murine fibrosarcoma cell line, 1.0/L1, were grown in ordinary flask cultures to determine appropriate cell inocula. Doses of agents were selected to reduce the final 4 day culture cellularity to about 50%, when present during the last two days of culturing. Secondly, the effects of these agents on cell numbers in the porous chambers and on cell migration out of the chambers ('emigration fraction') were recorded. We also examined, using a similar type of porous chamber, whether the agents could affect leucocyte chemotaxis. Hydroxyurea (an inhibitor of DNA synthesis) reduced cancer cell emigration as well as cell growth, without interfering with leucocyte chemotaxis. Cytochalasin B (a microfilament disrupting agent) inhibited cancer cell motility and growth, as well as leucocyte chemotaxis. Vinblastine (a microtubule disrupting agent), at the very low dose chosen, reduced cancer cell growth, but did not consistently affect the migration of either cell type. The experimental anti-metastasis agent Razoxane reduced growth, but had no detectable effects on motility. High doses of natural murine interferon-alpha/beta weakly inhibited both cancer cell growth and locomotion. This motivates for further studies of these and other cytokines, as treatment with agents inhibiting cancer cell locomotion might possibly prevent peri-operative spread of cancer in patients.

Animals↗
PubMed1997

Ameloblastic fibrosarcoma arising de novo in the maxilla.

An ameloblastic fibrosarcoma (AFS) arising in the maxilla of a 14-year-old male is described. The tumor originated from the alveolar bone of the right maxilla with no apparent history of pre-existing lesion. Histologically, the lesion was composed of benign-appearing epithelial islands and strands scattered within an exceedingly cellular mass of mesenchymal tissue comprising a large number of stellate-and spindle-shaped fibroblast-like cells with marked pleomorphism. Occasional cementum-like calcification was also noted. Immunohistochemically, the neoplastic mesenchymal cells were positive only for vimentin, whereas the ameloblast-like epithelial component showed a distinctly positive reaction for wide-spectrum keratin and squamous cytokeratin. Clinicopathological features of the current case, as well as previously reported examples of AFS originating from the maxilla, are briefly discussed.

Adolescent↗
PubMed1984

Ameloblastic fibrosarcoma: an ultrastructural study of the mesenchymal component.

The mesenchymal components of tumors from 2 patients with ameloblastic fibrosarcoma were studied ultrastructurally. The mesenchymal components consisted predominantly of fibroblastic cells with a few histiocytic or fibrohistiocytic cells and myofibroblastic cells. In addition, a very small number of undifferentiated mesenchymal cells were found. We speculate that the mesenchymal components in this tumor may be derived from the undifferentiated mesenchymal cells.

Adult↗
PubMed1987

Ameloblastic fibrosarcoma of the right mandible: immunohistochemical and electron microscopical investigations on one case, and a review of the literature.

A case of a 7-year-old girl with ameloblastic fibrosarcoma of the right mandible is described. Immunohistochemical techniques (detection of intermediate filaments, tissue polypeptide antigen, lactoferrin, lysozyme, Factor VIII-related protein, S-100 protein, carcinoembryonic antigen, alpha-foeto-protein, "lectin-receptors") and electron microscopy were applied. The epithelial part of the tumor, which was positive for keratin, showed distinct tonofilaments in electron microscopy. In contrast, the mesenchymal part was vimentin positive. The cells displayed the ultrastructural features of fibroblasts. The observations are compared with those reported in the literature.

Child↗
PubMed1998

The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form.

We have assessed the effect of fibronectin and laminin-1 on the expression of molecules involved in the activation pathway of MMP-2, a key proteinase in tissue remodelling. HT1080 fibrosarcoma cells cultured on fibronectin were shown to activate endogenous MMP-2, to a level comparable with that elicited by treatment with phorbol ester. In contrast, the MMP-2 expressed by HT1080 cells cultured on laminin-1 was mainly in the pro- (inactive form). Culture of the cells on peptide fragments of fibronectin derived from the central cell binding domain also promoted MMP-2 activation, indicating that signals via fibronectin binding to integrin receptors may be involved. HT1080 cells cultured on immobilised antibodies to the alpha5 and beta1 integrin subunits secreted levels of active MMP-2 similar to those observed for full length fibronectin, whereas cells cultured on an antibody to the alpha6 integrin subunit secreted mainly proMMP-2. The data demonstrate that the activation of MMP-2 by HT1080 cells is regulated by the nature of the extracellular matrix, and that signals via the alpha5beta1 integrin receptor may be involved in the fibronectin induced up-regulation of MMP-2 activation. We then assessed the effect of fibronectin on the components of the putative MT1-MMP/TIMP-2 'receptor' complex implicated in MMP-2 activation. Levels of TIMP-2 protein expressed by HT1080 cells did not vary detectably between cells cultured on fibronectin or laminin-1. However, the expression of MT1-MMP protein was up-regulated when the cells were cultured on fibronectin, which could be attributed to an increase in levels of a truncated 45 kDa form. Parallel studies using gelatin zymography demonstrated that the up-regulation of the production of the 45 kDa band was concomitant with MMP-2 activation. Inhibitor studies revealed that the truncation of MT1-MMP to a 45 kDa form is MMP mediated, although not inhibited by TIMP-1. In vitro, the 45 kDa form could be generated by cleavage of membrane-bound native MT1-MMP with several recombinant MMPs, including both active MT1-MMP and MMP-2. The implication that either MMP-2 or MT1-MMP can process MT1-MMP to 45 kDa, raises the possibility that truncation of MT1-MMP represents a self-regulatory end-point in the activation pathway of MMP-2.

Cell Adhesion↗
PubMedDate not supplied

Addition of mitomycin C to cis-diamminedichloroplatinum(II)/hyperthermia/radiation therapy in the FSaIIC fibrosarcoma.

Hyperthermia (temperatures greater than or equal to 42 degrees C) is used clinically to improve the effectiveness of radiation therapy and, although therapeutic gains have been reported, efficacy is limited when tumours are large and/or radiation tolerance is reduced. In order to improve the utility of the hyperthermia/radiation combination we have tested the addition of cisplatin (CDDP) in the laboratory and in the clinic. Our clinical studies have shown that the CDDP/hyperthermia/radiation combination is tolerable and effective, but laboratory investigations demonstrated a relative lack of cytotoxicity in the hypoxic tumour subpopulation. In order to improve the effectiveness of the CDDP/hyperthermia/radiation combination against hypoxic cells we have evaluated the addition of mitomycin C, a hypoxic cell cytotoxic agent to this combination. Mitomycin C (5 mg/kg) i.p. produced a tumour growth delay (TGD) of about 5.3 days in the FSaIIC murine fibrosarcoma; hyperthermia (43 degrees C x 30 min) caused only about 1.4 day TGD and the combination of mitomycin C followed immediately by hyperthermia caused a TGD of about 8.6 days. CDDP (5 mg/kg) i.p. followed by hyperthermia and then 3 Gy on day 1 only of a 5 day x 3 Gy radiation protocol produced a TGD of about 25 days. With the addition of mitomycin C just before CDDP a TGD of about 44 days resulted. Whole tumour excision experiments demonstrated that mitomycin C was highly interactive with CDDP at 37 degrees C and was dose-modifying. When used with CDDP and hyperthermia, however, mitomycin C added little additional cytotoxicity. Hoechst 33342 dye diffusion-determined tumour subpopulation studies indicated a marked effect of the addition of mitomycin C in the dim (enriched in hypoxic cells) subpopulation and nearby equal cytotoxicity in both bright (enriched in euoxic cells) and dim cells resulted. These investigations suggest considerable potential therapeutic efficacy to the addition of mitomycin C to the CDDP/hyperthermia/radiation combination.

Animals↗
PubMed1998

[An immunohistochemical study of the proliferating activity of ameloblastic fibroma and ameloblastic fibrosarcoma].

Six cases of ameloblastic fibroma (AF) and three cases of ameloblastic fibrosarcoma (AFS) were immunohistochemically investigated with a proliferating cell nuclear antigen (PCNA) monoclone antibody. Data on the PCNA labeling index (LI) of both epithelial and mesenchymal components were analyzed. The results showed that the PCNA LI of mesenchymal component of AFS (40.8%) was significantly higher than that of AF (3.2%) (P < 0.01) and that of the epithelial component of AFS (5.3%) was significantly lower than that of the mesenchymal one of AFS (P < 0.01). The results suggested that PCNA LI be a useful marker for the differentiation diagnosis of AF and AFS.

Cell Division↗
PubMed1990

Immunologic and survival studies in mice immunised with cryodestroyed ascites fibrosarcoma (AFS) cells.

Adult mice weighing 20 g, divided into 5 groups, were immunised with single and three cycle cryodestroyed ascites fibrosarcoma cells using different modes of immunisation with respect to dose and administration frequency. Survival against subsequent challenge with the same tumour cells and immune response given by leucocyte migration inhibition, were studied in these animals. It appears from the present study that animals with relatively low antigenic load have a significantly (P less than 0.001) high mean survival time and/or survival index compared with controls than those with relatively high antigenic load. Survival in animals immunised with three cycle cryodestroyed tumour cells is significantly (P less than 0.001) higher than that with single cycle even in face of a greater challenging tumour dose with mode of immunisation remaining the same. Preliminary observations on percentage leucocyte migration inhibition showed that there exists no difference in percentage inhibition with either viable or cryodestroyed tumour cell antigens added to migration chamber excepting in animals immunized with three cycle cryodestroyed tumour cells where percentage inhibition was significantly (P less than 0.001) greater with viable than with cryodestroyed tumour cell antigen without altering the percentage inhibition between the two groups. Factors maximising immune response and their modulating effects are discussed.

Animals↗
PubMed1979

Fibrosarcoma of breast metastatic to stomach.

A case of fibrosarcoma of the breast metastatic to the stomach and small bowel is reported. Upper gastrointestinal bleeding secondary to a "bull's eye" or "target" gastric ulcer was successfully treated by surgical resection.

Breast Neoplasms↗
PubMed1979

Immunity to a 3-methylcholanthrene-induced fibrosarcoma in the C57BL/6 mouse: in vivo analysis by the adoptive tumor neutralization test.

Analyses of the adoptive tumor neutralization test (modified Winn test) in C57BL/6 mice made immune to a 3-methylcholantheene-induced fibrosarcoma showed that the reaction was mediated by a thymus-derived lymphocyte, it was tumor-specific, and the resistance of the immunized donor mouse to the challenge was strongly correlated with the protection of the recipient mouse. Proliferation of immune cells and close contact between tumor cells and immune T-cells were required. The hypothesis of a participation of the recipient in the reaction was considered because of the lack of adoptive protection of pangenic nude mice.

Animals↗
PubMed1983

Metastasizing fibrosarcomas in hamsters (BMH) after injection of B77 sarcoma virus transformed mouse cells.

Injection of virogenic mouse cells B77-1026 into newborn Syrian hamsters resulted in arising of progressively growing autochthonous fibrosarcomas. From hamster tumors five stable tumor cell lines (BMH/1--BMH/5) were established in vitro. All cells of the newly established tumor cell lines had hamster karyotype, they were able to grow in soft agar and did not contain rescuable B77 viral genome. BMH tumor cells injected into syngeneic newborn as well as young adult hamsters produced tumors at the site of application and metastasized frequently into viscera. From metastases in different organs further tumor cell lines and single cell clones were established in vitro. All these tumor cell lines and clones exhibited higher metastatic capacity than the parent cell lines.

Animals↗